eLetters

131 e-Letters

published between 2005 and 2008

  • Looking for evidence for established facts?
    Bozidar Curkovic

    Dear Editor

    we read with interest recommendations for the management of ankylosing spondylitis by Zochling J et al (1). The autors made huge efforts to find and analise literature but final results seems to be questionable have these efforts been needed. In the recommendations we can see only one new treatment approach to the patients with ankylosing spondylitis (AS). Rheumatologists around the world many years ag...

    Show More
  • Reply to lupus thrombocytopenia - is it predictable?
    Michalis Voulgarelis

    Dear Editor,

    The answer is generally “No”.

    Antiphospholipid antibodies/ beta2-glycoprotein I complexes are associated with arterial and venous thrombosis, fetal loss and sometimes with thrombocytopenia, i.e. the antiphospholipid syndrome. However, immune-complex mediated platelet destruction is not a specific mechanism restricted to certain types of immune-complexes.

    Platelets have both immunoglo...

    Show More
  • Lupus thrombocytopenia - is it predictable?
    Prasanta Padhan

    Dear Editor,

    Thrombocytopenia in SLE results from various mechanisms and can be predicted in certain patients with high levels of immune complexes containing beta-2-glycoprotein I. They have also higher levels of serum lipoprotein(a). Thrombocytopenia is considered to be a component of a severe familial form of SLE. The genes at 1q22-23 and 11p13 are linked to this phenotype and to the subsequent high mortality associ...

    Show More
  • Effect of infliximab on bone mass in rheumatoid arthritis.
    Esther F. Vicente

    Dear Editor,

    We have read with great interest the article by Vis and colleagues discussing the effect of infliximab (IFX) on bone mass in patients with rheumatoid arthritis (RA).[1] Other studies show a diminished rate of lumbar spine (LS) BMD decline and an increase in femoral neck (FN) BMD after 54 weeks of IFX therapy,[2] whereas studies of bone loss in RA patients with active disease and without intervention show an...

    Show More
  • Ultrasound findings in healthy joints using two different contrast agents
    Andrea Sabine Klauser

    Dear Editor,

    In their article Terslev and colleagues [1] compared bolus administration of two different ultrasound (US) contrast agents to detect joint vascularity in healthy volunteers. We would like to offer several comments concerning use and behavior of US contrast media.

    First, bolus administration of Levovist and SonoVue when using colour/power Doppler (CDUS) results in strong blooming of colour sig...

    Show More
  • Cholesterol deposition in Rheumatoid Bursitis
    Marvin R Beard

    We were intrigued to find a similar case today of massive cholesterol deposition in Rheumatoid olecranon bursitis: BTH a 61YO caucasian male with a 20 year history of seropositive RA, hypertension and mild dyslipidemia presented with progressive, painless swelling of his olecranon bursa. He has had bursitis here for years with small nodularity quite consistent with RA nodules and bursitis. Joint fluid analysis revealed she...

    Show More
  • No association of smoking with anti-CCP antibodies in RA after adjustment for rheumatoid factor
    Derek L Mattey

    Dear Editor,

    We were interested to read the article by Linn-Rasker and colleagues who report that smoking is a risk factor for anti-cyclic-citrullinated (anti-CCP) antibodies only in RA patients that carry HLA-DRB1 shared epitope (SE) alleles.[1] They claim that an interaction is found between tobacco exposure (TE) and carriage of the SE which leads to anti-CCP production in RA. They find a similar effect for pres...

    Show More
  • Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus
    Gabriella Castellino

    Dear Editor,

    In their report on concentrations of TNF related apoptosis inducing ligand (TRAIL) in Systemic Lupus Erythematosus (SLE) patients, Lub-de Hooge et al stated that, notwithstanding SLE activity, TRAIL is increased in the serum of SLE patients compared to patients affected from Rheumatoid Arthritis (RA), Wegener’s granulomatosis and healthy subjects. Their study followed previous observations related to in...

    Show More
  • Comments on paper by Florance Tubach, et al.
    Volker Rahlfs

    Dear Editor,

    I would like to offer some comments on the paper: Evaluation of clinically relevant changes in patient-reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement by Florence Tubach, et al.

    The authors did a good job of collecting a mass of data and deriving a delta for the Minimal Clinically Important Improvement for the three core efficacy variables in osteo...

    Show More
  • HLA B27 is not an appropriate screening tool for spondyloarthropathy
    Paul J Healy

    Dear Editor,

    Sieper et al. propose a set of early referral criteria for ankylosing spondylitis (AS) using HLAB27 as an central test.[1] The supporting data were presented in a previous paper.[2] The HLAB27 data were taken from six study populations. In two groups the control population were either symptom free blood donors or no clinical data was known.[3, 4] There are three published trials using back pain contro...

    Show More

Pages